25-Hydroxyvitamin D testing and supplementation in CKD: An NKF-KDOQI controversies report

Holly Kramer, Jeffrey S. Berns, Michael J. Choi, Kevin Martin, Michael V. Rocco

Research output: Contribution to journalArticlepeer-review

Abstract

The benefits of and thresholds for 25-hydroxyvitamin D administration in individuals with chronic kidney disease (CKD) remain uncertain. In this report, NKF-KDOQI (National Kidney Foundation-Kidney Disease Outcomes Quality Initiative) endeavors to provide health care providers with the latest information on a controversial area in the management of CKD, the role for nutritional vitamin D. Although knowledge of the biological mechanisms of vitamin D for bone maintenance in individuals with all stages of CKD has expanded, no consensus currently exists within the medical community regarding methods for 25-hydroxyvitamin D supplementation or optimal 25-hydroxyvitamin D levels in individuals with CKD. Within this report, existing CKD guidelines are summarized and scrutinized and ongoing clinical trials are cited as sources for future guidance on the optimal management of vitamin D in CKD.

Original languageEnglish (US)
Pages (from-to)499-509
Number of pages11
JournalAmerican Journal of Kidney Diseases
Volume64
Issue number4
DOIs
StatePublished - Oct 1 2014

Keywords

  • 25-hydroxyvitamin D (25[OH]D)
  • NKF-KDOQI (National Kidney Foundation-Kidney Disease Outcomes Quality Initiative)
  • calcidiol
  • chronic kidney disease (CKD)
  • clinical practice guidelines
  • vitamin D deficiency

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of '25-Hydroxyvitamin D testing and supplementation in CKD: An NKF-KDOQI controversies report'. Together they form a unique fingerprint.

Cite this